Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

Technology appraisal guidance
Reference number: TA352
Published: 26 August 2015

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document
10 July 2015
(544.15 Kb 38 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 July 2015